Bharti Mangla
Overview
Explore the profile of Bharti Mangla including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
183
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kumar P, Mangla B, Akthar Imam S, Aggarwal G
Int J Pharm
. 2024 Aug;
664:124588.
PMID: 39153644
This study investigates the biodistribution of a nano lipid carrier system (NLCs) containing the hydrophobic drug erlotinib (ERL-NLCs). The system was labelled with the fluorescent dye IR-780 for real-time dynamic...
2.
Mangla B, Kumar P, Ahamad Z, Javed S, Ahsan W, Aggarwal G
Nanomedicine (Lond)
. 2024 Jul;
19(18-20):1659-1673.
PMID: 39056145
The aim of this study was to optimize, develop, characterize and evaluate a topical nanobigel (BG) formulation containing Berberine (BRB) that exhibits anti-melanogenic properties. The Berberine-loaded bigel (BRB@BG) formulation was...
3.
Mangla B, Mittal P, Kumar P, Aggarwal G
Med Oncol
. 2024 Jun;
41(7):173.
PMID: 38864966
Erlotinib (ELB) is a tyrosine kinase inhibitor that targets the activity of Epidermal Growth Factor Receptor (EGFR) protein found in both healthy and cancerous cells. It binds reversibly to the...
4.
Javed S, Mangla B, Sultan M, Almoshari Y, Sivadasan D, Alqahtani S, et al.
Heliyon
. 2024 May;
10(9):e29783.
PMID: 38694051
The issue of poor solubility of active pharmaceutical ingredients (APIs) has been a salient area of investigation and novel drug delivery systems are being developed to improve the solubility of...
5.
Saini A, Anil N, Vijay A, Mangla B, Javed S, Kumar P, et al.
Curr Pharm Des
. 2024 Apr;
30(19):1472-1489.
PMID: 38638052
Background: Friedreich's Ataxia (FRDA) is a rare hereditary neurodegenerative disorder characterized by progressive ataxia, cardiomyopathy, and diabetes. The disease is caused by a deficiency of frataxin, a mitochondrial protein involved...
6.
Development of erlotinib-loaded nanotransferosomal gel for the topical treatment of ductal carcinoma
Mangla B, Mittal P, Kumar P, Javed S, Ahsan W, Aggarwal G
Nanomedicine (Lond)
. 2024 Mar;
19(10):855-874.
PMID: 38440976
This study was aimed to formulate erlotinib (ERL)-loaded transferosomal gel (ERL@TG) intended for topical application for the treatment of ductal carcinoma . The optimized process involved a thin-film hydration method...
7.
Singh S, Mangla B, Javed S, Kumar P, Ahsan W
Anticancer Agents Med Chem
. 2023 Oct;
23(20):2237-2247.
PMID: 37807646
Background: Indenoisoquinoline-based compounds have shown promise as topoisomerase-I inhibitors, presenting an attractive avenue for rational anticancer drug design. However, a detailed QSAR study on these derivatives has not been performed...
8.
Kumar P, Mangla B, Javed S, Ahsan W, Aggarwal G
Nanomedicine (Lond)
. 2023 Sep;
18(18):1139-1160.
PMID: 37665053
This study aimed to improve the delivery and therapeutic potential of gefitinib (GTB) against breast cancer by preparing GTB-loaded, nanostructured lipid carriers (GTB-NLCs). Box-Behnken design was used for optimization and...
9.
Kumar V, Mangla B, Javed S, Ahsan W, Kumar P, Garg V, et al.
Food Funct
. 2023 Aug;
14(18):8101-8128.
PMID: 37650738
The utilization of plant-derived supplements for disease prevention and treatment has long been recognized because of their remarkable potential. , commonly known as pineapple, produces a group of enzymes called...
10.
Kumar P, Mangla B, Javed S, Ahsan W, Musyuni P, Sivadasan D, et al.
Front Pharmacol
. 2023 Jun;
14:1149554.
PMID: 37274111
Breast cancer being one of the most frequent cancers in women accounts for almost a quarter of all cancer cases. Early and late-stage breast cancer outcomes have improved dramatically, with...